These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22455398)

  • 1. Exploration of pipecolate sulfonamides as binders of the FK506-binding proteins 51 and 52.
    Gopalakrishnan R; Kozany C; Wang Y; Schneider S; Hoogeland B; Bracher A; Hausch F
    J Med Chem; 2012 May; 55(9):4123-31. PubMed ID: 22455398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of synthetic FK506 analogues as ligands for the FK506-binding proteins 51 and 52.
    Gopalakrishnan R; Kozany C; Gaali S; Kress C; Hoogeland B; Bracher A; Hausch F
    J Med Chem; 2012 May; 55(9):4114-22. PubMed ID: 22455444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescent probes to characterise FK506-binding proteins.
    Kozany C; März A; Kress C; Hausch F
    Chembiochem; 2009 May; 10(8):1402-10. PubMed ID: 19418507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKBP family proteins: immunophilins with versatile biological functions.
    Kang CB; Hong Y; Dhe-Paganon S; Yoon HS
    Neurosignals; 2008; 16(4):318-25. PubMed ID: 18635947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid, Structure-Based Exploration of Pipecolic Acid Amides as Novel Selective Antagonists of the FK506-Binding Protein 51.
    Gaali S; Feng X; Hähle A; Sippel C; Bracher A; Hausch F
    J Med Chem; 2016 Mar; 59(6):2410-22. PubMed ID: 26954324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the efficiency of ligands for FK506-binding protein 51 by conformational control.
    Wang Y; Kirschner A; Fabian AK; Gopalakrishnan R; Kress C; Hoogeland B; Koch U; Kozany C; Bracher A; Hausch F
    J Med Chem; 2013 May; 56(10):3922-35. PubMed ID: 23647266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prospect of FKBP51 as a drug target.
    Schmidt MV; Paez-Pereda M; Holsboer F; Hausch F
    ChemMedChem; 2012 Aug; 7(8):1351-9. PubMed ID: 22581765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting FKBP isoforms with small-molecule ligands.
    Blackburn EA; Walkinshaw MD
    Curr Opin Pharmacol; 2011 Aug; 11(4):365-71. PubMed ID: 21803654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural characterization of the PPIase domain of FKBP51, a cochaperone of human Hsp90.
    Bracher A; Kozany C; Thost AK; Hausch F
    Acta Crystallogr D Biol Crystallogr; 2011 Jun; 67(Pt 6):549-59. PubMed ID: 21636895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bifunctional molecules evade cytochrome P(450) metabolism by forming protective complexes with FK506-binding protein.
    Marinec PS; Lancia JK; Gestwicki JE
    Mol Biosyst; 2008 Jun; 4(6):571-8. PubMed ID: 18493655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total synthesis studies on macrocyclic pipecolic acid natural products: FK506, the antascomicins and rapamycin.
    Maddess ML; Tackett MN; Ley SV
    Prog Drug Res; 2008; 66():13, 15-186. PubMed ID: 18416305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Affinity Relationship Analysis of Selective FKBP51 Ligands.
    Feng X; Sippel C; Bracher A; Hausch F
    J Med Chem; 2015 Oct; 58(19):7796-806. PubMed ID: 26419422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
    Bauder M; Meyners C; Purder PL; Merz S; Sugiarto WO; Voll AM; Heymann T; Hausch F
    J Med Chem; 2021 Mar; 64(6):3320-3349. PubMed ID: 33666419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fragment-based synthesis and SAR of modified FKBP ligands: influence of different linking on binding affinity.
    Röhrig CH; Loch C; Guan JY; Siegal G; Overhand M
    ChemMedChem; 2007 Jul; 2(7):1054-70. PubMed ID: 17541991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemogenomic Profiling of Human and Microbial FK506-Binding Proteins.
    Pomplun S; Sippel C; Hähle A; Tay D; Shima K; Klages A; Ünal CM; Rieß B; Toh HT; Hansen G; Yoon HS; Bracher A; Preiser P; Rupp J; Steinert M; Hausch F
    J Med Chem; 2018 Apr; 61(8):3660-3673. PubMed ID: 29578710
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.
    Letavic MA; Axt MZ; Barberia JT; Carty TJ; Danley DE; Geoghegan KF; Halim NS; Hoth LR; Kamath AV; Laird ER; Lopresti-Morrow LL; McClure KF; Mitchell PG; Natarajan V; Noe MC; Pandit J; Reeves L; Schulte GK; Snow SL; Sweeney FJ; Tan DH; Yu CH
    Bioorg Med Chem Lett; 2002 May; 12(10):1387-90. PubMed ID: 11992783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pipecolic acid derivatives as small-molecule inhibitors of the Legionella MIP protein.
    Juli C; Sippel M; Jäger J; Thiele A; Weiwad M; Schweimer K; Rösch P; Steinert M; Sotriffer CA; Holzgrabe U
    J Med Chem; 2011 Jan; 54(1):277-83. PubMed ID: 21142106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of calcineurin inhibition by complexes of immunosuppressive drugs with human FK506 binding proteins.
    Weiwad M; Edlich F; Kilka S; Erdmann F; Jarczowski F; Dorn M; Moutty MC; Fischer G
    Biochemistry; 2006 Dec; 45(51):15776-84. PubMed ID: 17176100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomic structures of the human immunophilin FKBP-12 complexes with FK506 and rapamycin.
    Van Duyne GD; Standaert RF; Karplus PA; Schreiber SL; Clardy J
    J Mol Biol; 1993 Jan; 229(1):105-24. PubMed ID: 7678431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FK506 binding proteins as targets in anticancer therapy.
    Romano S; Di Pace A; Sorrentino A; Bisogni R; Sivero L; Romano MF
    Anticancer Agents Med Chem; 2010 Nov; 10(9):651-6. PubMed ID: 21182472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.